[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100457449":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":42,"centralContacts":11,"locations":45,"responsibleParty":59,"collaborators":11,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":11,"eligibilityCriteria":67,"healthyVolunteers":68,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":11,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":82,"whyStopped":11,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",[8,16,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment Sequence Group 1","EXPERIMENTAL",null,[13,14,15],"Drug: Atazanavir","Drug: Cobicistat","Drug: Atazanavir\u002FCobicistat Mini-tablet",{"label":17,"type":10,"description":11,"interventionNames":18},"Treatment Sequence Group 2",[13,14,15],{"label":20,"type":10,"description":11,"interventionNames":21},"Treatment Sequence Group 3",[13,14,15],[23,31,37],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","Atazanavir","Specified dose on specified days",[9,17,20],[29,30],"ATV","Reyataz",{"type":24,"name":32,"description":26,"armGroupLabels":33,"otherNames":34},"Cobicistat",[9,17,20],[35,36],"COBI","Tybost",{"type":24,"name":38,"description":26,"armGroupLabels":39,"otherNames":40},"Atazanavir\u002FCobicistat Mini-tablet",[9,17,20],[41],"Evotaz",[43],{"name":5,"affiliation":5,"role":44},"STUDY_DIRECTOR",[46],{"facility":47,"status":11,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":11},"Local Institution - 0001","Miami","Florida","33136","United States","US",{"type":54,"coordinates":55},"Point",[56,57],-80.19366,25.77427,{"lat":57,"lon":56},{"type":60,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100457449","phase-1-a-study-to-compare-the-drug-levels-of-atazanavir-and-cobicistat-between-the-coadministration-of-age-appropriate-mini-tablet-formulations-and-the-coadministration-of-the-individual-reference-products-in-healthy-adults-under-fed-conditions-100457449",false,"NCT05236738","A Study to Compare the Drug Levels of Atazanavir and Cobicistat Between the Coadministration of Age-Appropriate Mini-Tablet Formulations and the Coadministration of the Individual Reference Products in Healthy Adults Under Fed Conditions","An Open-Label, Randomized, Single-Dose, 3-Treatment, 3-Period, 3-Sequence, Crossover Design, Relative Bioavailability Study Comparing the Pharmacokinetics of Atazanavir and Cobicistat Between the Coadministration of Age-Appropriate Mini-Tablet Formulations (ATV and COBI Oral Mini-tablets; 300 mg and 150 mg, Respectively) and the Coadministration of the Individual Reference Products (REYATAZ [Atazanavir Oral Powder] and TYBOST [Cobicistat Oral Tablet]; 300 mg and 150 mg, Respectively) in Healthy Adults Under Fed Conditions","Inclusion Criteria:\n\n• Body Mass Index (BMI) of 18.0 to 32.0 kg\u002Fm\\^2, inclusive. BMI = weight (kg)\u002F\\[height(m)\\]\\^2\n\nExclusion Criteria:\n\n* Significant acute or chronic medical illness\n* History of a clinically significant drug rash, Stevens-Johnson Syndrome or Gilbert's Syndrome\n* Inability to swallow oral medication\n* Major surgery within 4 weeks of study treatment administration\n\nOther protocol-defined inclusion\u002Fexclusion criteria apply",true,"ALL","18 Years","49 Years",{"count":73,"type":74},42,"ACTUAL","INTERVENTIONAL",[77],"PHASE1","The purpose of this study is to evaluate the drug absorption of atazanavir and cobicistat between the coadministration of the mini-tablet formulations in applesauce or chocolate pudding followed by water and the coadministration of atazanavir oral powder in applesauce and cobicistat oral tablet followed by water in healthy adult participants.",[80],"Healthy Participants",[80,25,32,30,36,41],"COMPLETED","2022-10-27",{"date":85,"type":74},"2022-10-31",{"date":87,"type":74},"2022-05-13",{"date":89,"type":74},"2022-07-26",{"name":5,"class":6},1]